• Capricor Therapeutics (CAPR) Upgraded to “Buy” at Zacks Investment Research

    Capricor Therapeutics (NASDAQ:CAPR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, April 4th. The firm currently has a $1.50 price objective on the biotechnology company’s stock. Zacks Investment Research’s price …

    Read More
  • 0 0